Excess All-Cause Deaths during Coronavirus Disease Pandemic, Japan, January-May 2020

COVID-19 Japan SARS-CoV-2 all-cause deaths coronavirus disease excess deaths respiratory infections severe acute respiratory syndrome coronavirus 2 viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
03 2021
Historique:
entrez: 24 2 2021
pubmed: 25 2 2021
medline: 10 3 2021
Statut: ppublish

Résumé

To provide insight into the mortality burden of coronavirus disease (COVID-19) in Japan, we estimated the excess all-cause deaths for each week during the pandemic, January-May 2020, by prefecture and age group. We applied quasi-Poisson regression models to vital statistics data. Excess deaths were expressed as the range of differences between the observed and expected number of all-cause deaths and the 95% upper bound of the 1-sided prediction interval. A total of 208-4,322 all-cause excess deaths at the national level indicated a 0.03%-0.72% excess in the observed number of deaths. Prefecture and age structure consistency between the reported COVID-19 deaths and our estimates was weak, suggesting the need to use cause-specific analyses to distinguish between direct and indirect consequences of COVID-19.

Identifiants

pubmed: 33622468
doi: 10.3201/eid2703.203925
pmc: PMC7920666
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

789-795

Références

JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
Influenza Other Respir Viruses. 2013 Sep;7(5):863-71
pubmed: 23419002
PLoS Med. 2007 Aug;4(8):e247
pubmed: 17683196
Stat Med. 2013 Mar 30;32(7):1206-22
pubmed: 22941770
BMC Public Health. 2020 Aug 14;20(1):1238
pubmed: 32795276
Euro Surveill. 2017 Apr 6;22(14):
pubmed: 28424146
JAMA Intern Med. 2020 Oct 1;180(10):1336-1344
pubmed: 32609310
Lancet. 2020 May 23;395(10237):1602
pubmed: 32446403
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):603-605
pubmed: 32407306
PLoS One. 2017 Jul 17;12(7):e0181227
pubmed: 28715489
BMJ. 2020 Jul 17;370:m2859
pubmed: 32680851
Euro Surveill. 2020 Jul;25(26):
pubmed: 32643601
Lancet. 2020 May 30;395(10238):1715-1725
pubmed: 32405103
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872
pubmed: 32283124
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
Lancet. 2020 Jun 13;395(10240):1829
pubmed: 32473099

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH